ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Dustin M. Walters
Matched on ORCID iD 0000-0002-7346-9251; OpenAlex author ID A5062557528. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2011: 3 papers · 2012: none · 2013: 2 papers · 2014: 1 paper
Papers 6
- Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Co-author DOI 10.1016/j.neo.2014.06.004↗
- Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. Co-author DOI 10.1371/journal.pone.0077065↗
- Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epiderma… Co-author DOI 10.1593/neo.121712↗
- Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Co-author DOI 10.1158/1535-7163.mct-11-0261↗
- Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Co-author DOI 10.1245/s10434-010-1456-7↗
- Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-011-1693-4↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Todd W. Bauer · 6 shared papers, 2011–2014 · strength 0.19
- Paper Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xe… DOI 10.1016/j.neo.2014.06.004↗
- Paper Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fr… DOI 10.1371/journal.pone.0077065↗
- Paper Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented… DOI 10.1593/neo.121712↗
- Jayme B. Stokes · 5 shared papers, 2011–2013 · strength 0.14
- Paper Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fr… DOI 10.1371/journal.pone.0077065↗
- Paper Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented… DOI 10.1593/neo.121712↗
- Paper Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarc… DOI 10.1245/s10434-011-1693-4↗
- Timothy Eric Newhook · 2 shared papers, 2013–2014 · strength 0.08
- Paper Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xe… DOI 10.1016/j.neo.2014.06.004↗
- Paper Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented… DOI 10.1593/neo.121712↗
- James M. Lindberg · 2 shared papers, 2013–2014 · strength 0.08
- Paper Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xe… DOI 10.1016/j.neo.2014.06.004↗
- Paper Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented… DOI 10.1593/neo.121712↗
- Reid B. Adams · 2 shared papers, 2011 · strength 0.06
- Tyvin A. Rich · 1 shared paper, 2011 · strength 0.03
- Rosa F. Hwang · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.